Skip to main content
Springer logoLink to Springer
. 2019 Feb 19;37(6):869. doi: 10.1007/s40273-019-00773-w

Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Hema Mistry 1,, Chidozie Nduka 1, Martin Connock 1, Jill Colquitt 2, Theodoros Mantopoulos 1, Emma Loveman 2, Renata Walewska 3, James Mason 1
PMCID: PMC6830393  PMID: 30778866

Correction to: PharmacoEconomics (2018) 36:399–406 10.1007/s40273-017-0599-9

The Open Access license, which previously read:

Open Access: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Should read:

Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article was corrected.


Articles from Pharmacoeconomics are provided here courtesy of Springer

RESOURCES